By Using Mind.Px, Patients Achieve PASI75 Faster than Treatment-as-Usual Cohort

SAN DIEGO, CA – October 20, 2022 – Interim clinical utility and patient outcomes data regarding Mindera Health’s Mind.Px^™ test from the ongoing MATCH study were recently presented at the Fall Clinical Dermatology Conference 2022 in Las Vegas, one of the largest US-based dermatology educational meetings. These data validate the willingness of physicians to incorporate Mind.Px test results into their biologic decision making for psoriasis patients as well as demonstrate improved patient outcomes when the test reports were followed.

In the United States, psoriasis affects more than three percentⁱ of the population, leading to healthcare costs of more than $110 billion annually.ⁱⁱ Furthermore, successful patient responses to currently available biologic treatments are roughly 52 percentⁱⁱⁱ, leading to trial-and-error patient treatments and increased healthcare costs. Mind.Px is a predictive test used to improve management of psoriasis patients and allows physicians to prescribe biologic drugs with >92 percent positive predictive value.

The poster Trial-And-Error Prescribing Behavior Is Modified By A Psoriasis Precision Medicine Tool: Preliminary Clinical Utility Findings From The Match Study, led by Bruce E. Strober, MD, PhD, et al., was designed to evaluate the clinical utility of the Mind.Px diagnostic test in physician decision making and patient outcomes.

The interim results for this randomized study include 115 patients from 31 sites across the US over a 16-week treatment period, with roughly half of the patients randomized to the Mind.Px-informed arm versus a treatment-as-usual arm. Physicians were provided test results prior to biologic selection in the Mind.Px-informed arm. The study’s findings demonstrate:

• 88 percent of physician therapeutic choices that initiated dosing were aligned with Mind.Px test results; the primary reason to not follow the results were restrictions from insurance formularies;
• Only 55 percent of physician therapeutic choices were consistent with Mind.Px test results in the treatment-as-usual arm, supporting the previously published trial-and-error challenge for psoriasis patient management when prescribing biologic drugs; and
• An interim analysis of patients who have completed the MATCH study shows that by using Mind.Px results, patients reach clinical endpoints (PASI75) faster than those in the treatment-as-usual arm.

Mindera Health Chief Scientific Officer and Co-Founder Tobin J. Dickerson, PhD, stated, “These exciting interim data show that by using Mind.Px test results, patients reach clinical endpoints faster in a statistically significant manner. This is a key milestone in demonstrating the clinical utility of the test and, ultimately, incorporation into clinical practice.”

“Use of Mind.Px can effectively minimize the trial-and-error approach to psoriasis treatment and provide physicians, patients, and payers with a powerful tool for re-envisioning psoriasis patient care — the true vision of precision medicine,” commented George Mahaffey, President and CEO of Mindera Health.

About Mind.Px^™
Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample along with data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments.

About Mindera Health^™
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.

---

ⁱMenter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057.

ⁱⁱPilon D, Teeple A, Zhdanava M, et al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. J Med Econ. 2019;22(2):196-203. doi:10.1080/13696998.2018.1557201.

ⁱⁱⁱEnos CW, et al. Psoriasis severity, comorbidities, and treatment response differ among geographic regions in the United States. JID Innovations. 2021;1:100025.

Deren-Lewis will lead the company’s aggressive commercialization plans for the first personalized medicine platform specific to the dermatology industry.

(SAN DIEGO, CA – August 2, 2021) Mindera Corporation, developers of the groundbreaking Dermal Intelligence™ platform – the first realization of personalized medicine in dermatology – has appointed renowned industry veteran Ann Deren-Lewis as its Chief Commercial Officer.  Deren-Lewis brings over 30 years of leadership experience to the company with a proven track record in marketing, sales, product development, medical affairs and corporate development for Fortune 500 companies and start-ups.  She is a recognized leader in the dermatology industry and was one of the first non-dermatologists to become a member of the American Academy of Dermatology.

At Mindera, Deren-Lewis will lead the company’s commercial launch and growth plan for its Mind.Px, the organization’s flagship test to prospectively predict a patient’s response to expensive biologic drugs for psoriasis and other skin conditions.  Her primary initiatives will include building out the company’s systems and processes to maximize efficiencies, expanding the commercialization team to position Mind.Px for rapid adoption, and pioneering educational efforts with key opinion leaders in the dermatology industry.

“Ann has the demonstrated ability and distinct set of skills to support Mindera’s efforts to shape the era of digital predictive skin analytics and lead the market in Dermal Intelligence,” said George Mahaffey, CEO of Mindera. “Her experience in commercializing medical and aesthetic products and services, with an emphasis on psoriasis, is a perfect fit with our needs.”

“I have a passion for moving the needle on novel technologies,” commented Deren-Lewis. “The Mindera platform is one of the most innovative platforms I’ve seen and truly holds the potential to improve patient outcomes and decrease cost of care, and I am thrilled to be a part of the company.”

Deren-Lewis most recently served as Sr. Vice President of Corporate Development at Zerigo Health (formerly Clarify Medical) where she led commercial operations, including sales, marketing, medical affairs, and the clinical care team. Previously, Deren-Lewis was Founder and Principal of Two Blue Consulting working with a variety of clients in the medical and consumer goods industries.. She also holds boards seats with Afecta Phramaceuticals and Yorkshire Square Brewery.

Deren-Lewis holds a Master of Business Administration degree from Duke University and a Bachelor of Science degree from the University of North Carolina-Wilmington. 

About Mind.Px

Mind.Px is the flagship test of Mindera Corporation.  The Mindera platform uses a dermal biomarker patch that takes only minutes to extract vast transcriptomic information. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera scientists to take a genetic and transcriptomic snapshot of the skin. This rich patient-specific data set is then analyzed by machine learning algorithms to predict the appropriate biologic drug for an individual patient prior to therapeutic selection and treatment. The ability to collect patient data at scale results in a powerful platform that unlocks cost savings for healthcare systems, particularly when applied to the prediction of response to hyper-expensive treatments. Biomarkers captured using the Mindera platform include DNA, RNA, protein, and small molecules.

About Mindera

Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level.  Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes.  Mindera is a CLIA and CAP certified Laboratory and has received ISO 13485:2016 certification.  Find out more at www.minderahealth.com.

Study shows 98% of dermatologists would utilize Mind.Px to predict biologic response for psoriasis patients

SAN DIEGO – July 26, 2021 – Mindera Corporation today announced that Dermatology and Therapy published results from a survey of 43 community-based dermatologists on behaviors and preferences of psoriasis-treating physicians.  The survey revealed a widespread and costly trial-and-error cycle in psoriasis biologic decision making, resulting in suboptimal patient outcomes and high wasted spending by payers.

Additionally, physicians expressed enthusiasm for Mind.Px™, a new precision medicine test that predicts individual patient response to psoriasis biologic classes with a high level of predictive value before a physician selects a biologic.  In contrast to the current trial-and-error prescribing behavior, the survey revealed that dermatologists view Mind.Px as a move towards dermatologic precision medicine.  Highlights of survey findings include:

• 82% of dermatologists report switching biologics for 10-30% of their patients within the first year of prescription
• 93% of dermatologists would utilize the Mind.Px test results over their own initial clinical choice
• 100% of dermatologists would use Mind.Px if it were integrated into the prior authorization process
• 98% of dermatologists say that Mind.Px would improve patient outcomes

The study was authored by key opinion leaders and authors of the Joint American Academy of Dermatology/National Psoriasis Foundation Guidelines of Care for the Management and Treatment of Psoriasis with Biologics, including Bruce Strober, MD PhD, David Pariser MD, Mark Lebwohl, MD, and Alan Menter, MD.  The guidelines, published in 2019, stated that there is “an important need to identify biomarkers that can potentially predict the appropriate biologic agent of individual patients.”

“Having the ability to proactively predict response to a biologic class with Mind.Px will enable physicians to finally have a tool to better prescribe the appropriate therapy the first time, significantly improving patient outcomes,” said Dr. Strober. “The potential benefits to the patient and the healthcare system are groundbreaking and the survey clearly shows the perceived clinical utility of this test.”

Mind.Px is the flagship test of Mindera Corporation.  The Mindera platform uses a dermal biomarker patch that takes only minutes to extract vast transcriptomic information. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera scientists to take a genetic and transcriptomic snapshot of the skin. This rich patient-specific data set is then analyzed by machine learning algorithms to predict the appropriate biologic drug for an individual patient prior to therapeutic selection and treatment.

The ability to collect patient data at scale results in a powerful platform that unlocks cost savings for healthcare systems, particularly when applied to the prediction of response to hyper-expensive treatments. Biomarkers captured using the Mindera platform include DNA, RNA, protein, and small molecules.

About Mindera Health

Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level.  Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes.  Mindera is a CLIA and CAP certified Laboratory and has received ISO 13485:2016 certification.  Find out more at www.minderahealth.com.

Model yielded average cost savings per patient of $8,492 annually as well as an average annual wasted spend savings of $16,567

SAN DIEGO – July 19, 2021 – Mindera Corporation today announced that SKIN: The Journal of Cutaneous Medicine has published “An economic evaluation of the budget impact of precision medicine testing for the treatment of psoriasis”. The primary objective of this study was to determine the potential cost savings from a precision medicine approach in the selection of biologics for psoriasis patients. The evaluation projected the cost savings of multiple formulary scenarios, simulated through the Budget Impact Model (BIM). Based on the analysis of a subset of payers representing various formulary structures, the model yielded average cost savings per patient of $8,492 annually as well as an average annual wasted spend savings of $16,567 per patient.

“In the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) guidelines, we identified the need for biomarkers to predict patient response to therapy,” said Jashin J. Wu, MD, lead author of the study. “Having a test like Mind.Px will enable us to better select the appropriate biologic for our patients.”

“Healthcare systems are looking to precision medicine to improve patient outcomes while increasing physician and patient satisfaction. Importantly, these advances should provide significant savings and avoid wasted spending,” added George Mahaffey, President and CEO of Mindera. “Mindera is positioned to be the first to make precision medicine a reality in psoriasis and other chronic skin diseases to meet the needs of patients, physicians, and payers.”

The study can be found here: https://jofskin.org/index.php/skin/article/view/1316.

About Mind.Px

Mind.Px is the flagship test of Mindera Corporation. The Mindera platform uses a dermal biomarker patch that takes only minutes to extract vast transcriptomic information. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera scientists to take a genetic and transcriptomic snapshot of the skin. This rich patient-specific data set is then analyzed by machine learning algorithms to predict the appropriate biologic drug for an individual patient prior to therapeutic selection and treatment.

The ability to collect patient data at scale results in a powerful platform that unlocks cost savings for healthcare systems, particularly when applied to the prediction of response to hyper-expensive treatments. Biomarkers captured using the Mindera platform include DNA, RNA, protein, and small molecules.

About Mindera

Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level.  Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes.  Mindera is a CLIA and CAP certified Laboratory and has received ISO 13485:2016 certification.  Find out more at www.minderahealth.com.

SAN DIEGO – May 11, 2021 – Mindera Corporation today announced a $12.6M Series A-2 capital raise.  The round was led by Mountain Group Partners, Rockmont Investments, and Scientific Health Development.  The funding will be used to commercialize Mind.Px, a groundbreaking tool to prospectively predict patient response to expensive psoriasis biologics, as well as continue development of the Mindera Dermal Intelligence™ Platform.

The Mindera platform uses a simple patch that extracts biomarkers from the skin in minutes, allowing for rapid and painless extraction of RNA. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera scientists to take a genetic and transcriptomic snapshot of the skin at the exact moment of the test. In the case of Mind.Px, this rich patient-specific data is then analyzed by proprietary machine learning algorithms to predict the appropriate psoriasis biologic drug for a patient prior to therapeutic selection and treatment.

Mind.Px is a first-of-its-kind precision medicine dermatology solution that aligns patient, physician, and payer interests by predicting effective biologics for individuals, avoiding trial-and-error prescription behavior and wasted payer spending. 

For more information, contact info@minderahealth.com.

About Mindera

Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level.  Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes.  Mindera is a CLIA and ISO 13485 certified Laboratory.  Find out more at www.minderahealth.com.

Mindera dermal biomarker patch technology generates clinically validated data to lower healthcare costs and improve patient outcomes

SAN DIEGO – May 6, 2021 – Mindera Corporation today announced that it has been selected as the winner of the “Best New Technology Solution for Dermatology” award in the fifth annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market.

The Mindera platform uses a simple patch that takes only minutes to extract biomarkers, allowing for simple, minimally invasive, rapid and painless extraction of RNA from the skin using a dermal biomarker patch. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera scientists to take a genetic and transcriptomic snapshot of the skin at the exact moment of the test. This rich patient-specific data set is then analyzed by machine learning algorithms to ask sophisticated questions of the data, for example, predicting the appropriate biologic drug for a patient prior to therapeutic selection and treatment.

The ability to collect patient data at scale, combined with high precision molecular testing, results in a powerful platform with improved sensitivity and specificity, translating into huge cost savings for healthcare systems, particularly when applied to the prediction of response to hyper-expensive treatments. Biomarkers captured using the Mindera platform include DNA, RNA, protein, and small molecules; in particular, the role of RNA in chronic skin diseases is well characterized.

“Patients get the right biologic the first time and have improved outcomes while the payers save wasted dollars that were the result of being a non-responder to treatment. Precision medicine is an integrated approach to better patient outcomes,” said George Mahaffey, CEO of Mindera. “We’re proud of our platform and equally proud to receive this recognition from MedTech Breakthrough with this 2021 MedTech Breakthrough Award win.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Robotics, Clinical Administration, Telehealth, Patient Engagement, Electronic Health Records (EHR), mHealth, Medical Devices, Medical Data and many more. This year’s program attracted more than 3,850 nominations from over 17 different countries throughout the world.

“Mindera’s digital predictive skin analytics platform represents a significant dermatology breakthrough, allowing for a dramatic improvement in how patients are diagnosed and treated,” said James Johnson, managing director, MedTech Breakthrough. “This is taking MedTech to its highest level – being able to target treatment to each individual patient. Congratulations to Mindera for their for their success and innovation, taking home a well-deserved award win for ‘Best New Technology Solution for Dermatology’.”

About Mindera

Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level.  Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes.  Mindera is a CLIA and ISO 13485 certified Laboratory.  Find out more at www.minderahealth.com.

 About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is an independent program devoted to honoring excellence in medical and health related technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough health and medical companies and products in categories that include Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com. 

SAN DIEGO, CA – Mindera Corporation announced that it has won the prestigious Terra2 Skin Health Innovations Competition at the 2021 Winter Clinical Dermatology Conference.  The Winter Clinical Dermatology Conference is an annual conference for dermatologists and dermatology residents to further education and discuss breakthrough innovations in their specialty.

Tobin Dickerson, Ph.D., Chief Scientific Officer and Co-founder of Mindera, presented Mind.Px, a Precision Medicine test to predict a patient’s personalized response to psoriasis biologics.  Led by a panel of leading experts, an audience of hundreds of dermatologists voted for Mindera in recognition of its revolutionary technology and implications on everyday clinical practice.  “We are honored to be selected as the winner of the Terra2 Skin Health Innovations Competition.  The recognition is rewarding for our entire team, and is a testament to the hard work that has been put into making Mind.Px a reality.  We eagerly look forward to bringing Mind.Px to the market later this year.”

Using Mindera’s proprietary FDA Registered dermal biomarker patch, the Mindera platform allows for minimally invasive extraction of rich biomarker data from individual patient skin. Captured molecules are sent to the Mindera CLIA-certified lab for analysis. Using Machine Learning, these baseline biomarkers can be correlated to clinical outcomes data from psoriasis patients who received specific biologic drugs, resulting in continuous evolving and improving predictive analyses for personalized drug responses. Systemwide, predicting biologic responses using Mind.Px can result in both improved psoriasis patient outcomes and billions of dollars of annual cost avoidance to the healthcare system.

About Mindera:

Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level.  Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes.  Mindera is a CLIA certified Laboratory.  Find out more at www.minderahealth.com.

SAN DIEGO, CA – Mindera Corporation announced that it has been selected as a finalist in the Terra2 Solutions Skin Heath Innovation Conference at the Winter Clinical Dermatology Conference.  Mindera will be presenting Mind.Px, its flagship Precision Medicine test for predicting patient response to psoriasis biologics.  The competition highlights companies that have developed new technologies and emerging solutions in dermatology, and will be judged by a panel of experts and conference attendees.

“We are proud to have been chosen as a finalist in the competition,” said George Mahaffey, CEO of Mindera.  “Our platform opens up the exciting field of Precision Medicine to dermatology, and we are looking forward to sharing this leap forward in technology with the many future thought leaders and decision makers in dermatology clinics across the country.”

Using Mindera’s proprietary FDA Registered dermal biomarker patch, the Mindera platform allows for minimally invasive extraction of rich biomarker data from individual patient skin. Captured molecules are sent to the Mindera CLIA-certified lab for analysis. Using Machine Learning, these baseline biomarkers can be correlated to clinical outcomes data from psoriasis patients who received specific biologic drugs, resulting in continuous evolving and improving predictive analyses for personalized drug responses. Systemwide, predicting biologic responses using Mind.Px can result in both improved psoriasis patient outcomes and billions of dollars of annual cost avoidance to the healthcare system.

About Mindera:

Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level.  Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes.  Mindera is a CLIA certified Laboratory.  Find out more at www.minderahealth.com.

SAN DIEGO, CA – Mindera Corporation announced that it has been invited to present Mind.Px, their flagship Precision Medicine test for predicting patient response to psoriasis biologics, at the 8^th Annual Dermatology Summit.  The Dermatology Summit is the premier national commercial dermatology conference and is timed to coincide annually with the J.P. Morgan Healthcare Conference. 

Featured in the Summit’s “Entrepreneurial Company Showcase”, Tobin Dickerson, Ph.D., Chief Scientific Officer and Co-founder of Mindera , will be presenting Mind.Px, a test to predict patient response to expensive psoriasis biologics before prescription. 

“We thank the organizers of the Dermatology Summit for the opportunity to present our work,” said Dr. Dickerson. “Providing physicians, patients, and payers critical baseline biomarker measurements correlated with clinical outcomes data will bring Personalized Medicine to the dermatology community. Proper pre-treatment choice of biologics will improve clinical outcomes while significantly lowering specialty drug costs to the overall healthcare system. We look forward to introducing Mind.Px to the dermatology community in 2021.”

Mind.Px is Mindera’s first application of its novel Precision Medicine platform for dermatology.  Using Mindera’s proprietary FDA registered dermal biomarker patch, the Mindera platform allows for minimally invasive extraction of rich biomarker data from individual patient skin. Captured molecules are sent to the Mindera CLIA-certified lab for analysis. Using Machine Learning, these baseline biomarkers can be correlated to clinical outcomes data from psoriasis patients who received specific biologic drugs, resulting in continuous evolving and improving predictive analyses for personalized drug responses. Systemwide, predicting biologic responses using Mind.Px can result in both improved psoriasis patient outcomes and billions of dollars of annual cost avoidance to the healthcare system.

For more information on the Dermatology Summit, please visit dermsummit.com.

About Mindera:

Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level.  Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes.  Mindera is a CLIA certified Laboratory.  Find out more at www.minderahealth.com.